Related Experiment Video
Updated: May 3, 2026
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
Recreational MDMA doses do not elicit hepatotoxicity in HepG2 spheroids under normo- and hyperthermia
Arthur L de Oliveira1, Raul G Miranda2, Daniel J Dorta1
1Department of Chemistry, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP 14040-901, Brazil.
Abstract:
MDMA (3,4-methylenedioxymethamphetamine), an entactogen with empathogenic and prosocial effects, is widely used in music festivals and other festive settings. High MDMA doses have been associated with drug-induced liver injury and cases of hyperthermia. Although the latter condition is thought to increase MDMA hepatotoxicity, this correlation remains poorly explored for recreational MDMA doses. On the other hand, the fact that MDMA acts to extinguish fear and to reconsolidate memory could be explored as an adjunct to psychotherapy during treatment of neuropsychiatric disorders such as post-traumatic stress disorder. In this context, assessing MDMA toxicity is relevant, and tridimensional cell culture has emerged as an alternative to animal models in toxicity assessment. Herein, we have used HepG2 spheroids to evaluate MDMA-induced hepatotoxicity at recreational doses, under normo- or hyperthermia. The MTT reduction assay did not evidence significantly reduced cell viability. Moreover, MDMA did not increase reactive oxygen species production, deplete the mitochondrial membrane potential, arrest the cell cycle, or induce apoptotic cell death. These findings support further pre-clinical investigation of MDMA safety from the perspective of both harm reduction and therapy given that non-abusive recreational and therapeutic doses overlap.
Insights
Recreational doses of 3,4-methylenedioxymethamphetamine (MDMA) did not cause liver damage in lab tests, even with increased heat. This suggests MDMA may be safer for therapeutic use and harm reduction than previously thought.
Area of Science:
- Pharmacology
- Hepatotoxicity
- Neuroscience
Background:
- 3,4-methylenedioxymethamphetamine (MDMA) is known for its empathogenic effects and use in recreational settings.
- High doses of MDMA are linked to liver injury and hyperthermia, but the impact of recreational doses on hepatotoxicity is not well understood.
- MDMA's effects on fear extinction and memory reconsolidation suggest potential therapeutic applications in neuropsychiatric disorders like PTSD.
Purpose of the Study:
- To evaluate the hepatotoxicity of MDMA at recreational doses using a 3D cell culture model.
- To investigate the influence of normothermia versus hyperthermia on MDMA-induced liver injury.
- To assess the safety profile of MDMA for potential therapeutic and harm reduction purposes.
Main Methods:
- Utilized HepG2 spheroids as a 3D cell culture model for toxicity assessment.
- Administered MDMA at recreational doses under both normothermic and hyperthermic conditions.
- Assessed cell viability using the MTT reduction assay and evaluated markers of cellular stress, including reactive oxygen species, mitochondrial membrane potential, cell cycle arrest, and apoptosis.
Main Results:
- MDMA at recreational doses did not significantly reduce cell viability in HepG2 spheroids.
- No significant increase in reactive oxygen species production was observed.
- MDMA did not induce mitochondrial dysfunction, cell cycle arrest, or apoptotic cell death, even under hyperthermic conditions.
Conclusions:
- MDMA at recreational doses does not appear to cause significant hepatotoxicity in the HepG2 spheroid model.
- The findings support the potential for further pre-clinical investigation into MDMA's safety for both harm reduction and therapeutic applications.
- The overlap between recreational and therapeutic doses warrants continued research into MDMA's safety profile.
Related Concept Videos
01:25Increased Body Temperature
01:19Homeostatic Imbalances in Body Temperature
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:24Drug Toxicity: Dose-Dependent Reactions
01:25Hepatitis